Phase 2 Data on Provectus's PV-10 for Metastatic Melanoma to Be Presented at ... - Business Wire (press release)

Phase 2 collection on Provectus's PV-10 for Metastatic Melanoma to Be Presented at ... business concern Wire (press release) Its dermatological drug PH-10 too targets abnormal or pathologic cells, with the actual focus on psoriasis and atopic dermatitis. Provectus has recently completed its state of matter 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a ... Provectus (OTCBB: PVCT) to Present Phase 2 PV-10 for Metastatic Melanoma At ... BiotechStockTrader.com all xiv news articles » Link To Article